diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM13086diaendo-13086Research ArticleНовостиNewsРоль канаглифлозина в профилактике инсульта и хронической болезни почек у пациентов с сахарным диабетом 2 типа: резолюция совета экспертовThe role of canagliflozin in the prevention of stroke and chronic kidney disease in patients with type 2 diabetes mellitus: an expert council resolutionhttps://orcid.org/0000-0002-5057-127XШестаковаМ. В.ShestakovaM. V.

Шестакова Марина Владимировна - доктор медицинских наук, профессор, академик РАН.

117036, Москва, ул. Дм. Ульянова, д. 11

Marina V. Shestakova - MD, PhD, Professor.

11 Dm. Ulyanova str., Moscow, 117036

nephro@endocrincentr.ruhttps://orcid.org/0000-0001-6581-4521ГалстянГ. Р.GalstyanG. R.

Галстян Гагик Радикович - доктор медицинских наук, профессор.

Москва

Gagik R. Galstyan - MD, PhD, Professor.

Moscow

galstyangagik964@gmail.comhttps://orcid.org/0000-0003-0042-7680ГриневаЕ. Н.GrinevaE. N.

Гринёва Елена Николаевна - доктор медицинских наук, профессор.

Санкт-Петербург

Elena N. Grineva - MD, PhD, Professor.

St. Petersburg

grineva_e@mail.ruhttps://orcid.org/0000-0003-3494-8011ЗиловА. В.ZilovA. V.

Зилов Алексей Вадимович – кандидат медицинских наук, доцент.

Москва

Alexey V. Zilov - MD, PhD, Assistant Professor.

Moscow

azilov@hotmail.comДемидоваТ. Ю.DemidovaT. Yu.

Демидова Татьяна Юльевна - доктор медицинских наук, профессор.

Москва

Researcher ID: D-3425-2018; Author ID: 7003771623

Tatiana Y. Demidova - MD, PhD, Professor.

Moscow

Researcher ID: D-3425-2018; Author ID: 7003771623

y.demidova@gmail.comhttps://orcid.org/0000-0003-1316-5245МкртумянА. М.MkrtumyanA. M.

Мкртумян Ашот Мусаелович - доктор медицинских наук, профессор.

Москва

Author ID: 513441

Ashot M. Mkrtumyan - MD, PhD, Professor.

Moscow

Author ID: 513441

vagrashot@mail.ruhttps://orcid.org/0000-0001-9390-1200ПетунинаН. А.PetuninaN. A.

Петунина Нина Александровна - доктор медицинских наук, профессор.

Москва

Nina A. Petunina - MD, PhD, Professor.

Moscow

napetunina@mail.ruhttps://orcid.org/0000-0002-6762-5238РуяткинаЛ. А.RuyatkinaL. A.

Руяткина Людмила Александровна - доктор медицинских наук, профессор.

Новосибирск

Lyudmila A. Ruyatkina - MD, PhD, Professor.

Novosibirsk

larut@list.ruhttps://orcid.org/0000-0002-3443-7206СухареваО. Ю.SukharevaO. Y.

Сухарева Ольга Юрьевна – кандидат медицинских наук, доцент.

Москва

Olga Sukhareva - MD, PhD.

Moscow

olgasukhareva@mail.ruhttps://orcid.org/0000-0001-9253-8075СуплотоваЛ. А.SuplotovaL. A.

Суплотова Людмила Александровна - доктор медицинских наук, профессор.

Тюмень

Lyudmila A. Suplotova - MD, PhD, Professor.

Tyumen

suplotovala@mail.ruhttps://orcid.org/0000-0002-3433-0142ШамхаловаМ. Ш.ShamkhalovaM. S.

Шамхалова Минара Шамхаловна - доктор медицинских наук

Москва

Minara S. Shamhalova - MD, PhD.

Moscow

shamkhalova@mail.ruГНЦ РФ ФГБУ «НМИЦ эндокринологии» Минздрава РоссииРоссияEndocrinology Research CentreRussian FederationНациональный исследовательский медицинский центр им. В.А. АлмазоваРоссияV.A. Almazov National Medical Research CenterRussian FederationПервый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian FederationМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovaRussian FederationНовосибирский государственный медицинский университетРоссияNovosibirsk State Medical UniversityRussian FederationТюменский государственный медицинский университетРоссияTyumen State Medical UniversityRussian Federation202323102023265484491Copyright © Шестакова М.В., Галстян Г.Р., Гринева Е.Н., Зилов А.В., Демидова Т.Ю., Мкртумян А.М., Петунина Н.А., Руяткина Л.А., Сухарева О.Ю., Суплотова Л.А., Шамхалова М.Ш., 20232023Шестакова М.В., Галстян Г.Р., Гринева Е.Н., Зилов А.В., Демидова Т.Ю., Мкртумян А.М., Петунина Н.А., Руяткина Л.А., Сухарева О.Ю., Суплотова Л.А., Шамхалова М.Ш.Shestakova M.V., Galstyan G.R., Grineva E.N., Zilov A.V., Demidova T.Y., Mkrtumyan A.M., Petunina N.A., Ruyatkina L.A., Sukhareva O.Y., Suplotova L.A., Shamkhalova M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/13086

За последние 10 лет изучения осложнений сахарного диабета 2 типа (СД2) и способов борьбы с ними удалось добиться существенного прогресса по одному из наиболее важных направлений лечения — профилактике кардиоваскулярных и почечных осложнений. Так, при использовании ингибиторов натрий-глюкозного котранспортера 2 типа (иНГЛТ-2) было доказано существенное снижение рисков сердечно-сосудистой смертности и прогрессирования хронической сердечной недостаточности, которые занимают основное место в структуре смертности в данной когорте пациентов, а также положительное влияние на диабетическую нефропатию, одно из наиболее часто встречаемых осложнений СД2. Тем не менее остаются и другие осложнения, существенно влияющие на продолжительность и качество жизни пациентов. В частности, к ним относятся инсульт, занимающий 2-3 место по частоте смерти людей с СД2, и альбуминурия — частное проявление диабетической болезни почек, которое ассоциируется с повышенными рисками возникновения сердечно-сосудистых осложнений (в том числе и инсульта) и хронической почечной недостаточности. Недавние исследования свидетельствуют о важной роли НГЛТ-1 в развитии указанных осложнений. Наибольшим сродством к данным транспортерам из зарегистрированных в РФ иНГЛТ-2 обладает канаглифлозин. Настоящая статья призвана оценить механизмы действия канаглифлозина и его возможную роль в предотвращении развития инсульта и альбуминурии.

Over the past 10 years of studying the complications of type 2 diabetes mellitus (DM) and ways to deal with them, significant progress has been made in one of the most important areas of treatment — the prevention of cardiovascular and renal complications. Thus, when using inhibitors of type 2 sodium-glucose cotransporter, a significant reduction in the risks of cardiovascular mortality and progression of chronic heart failure, which occupy the main place in the structure of mortality in this cohort of patients, as well as a positive effect on diabetic nephropathy, one of the most common complications of type 2 diabetes, has been proven. However, there are other complications that significantly affect the duration and quality of life of patients. In particular, these include stroke, which occupies the 2nd-3rd place in the frequency of death of people with type 2 diabetes, and albuminuria, a frequent manifestation of diabetic kidney disease, which is associated with an increased risk of cardiovascular complications (including stroke) and chronic renal failure. Recent studies indicate the important role of sodium-glucose cotransporter type 1 in the development of these complications. Canagliflozin has the highest affinity for these transporters among iSGLT-2 registered in the Russian Federation. This article aims to evaluate the mechanisms of action of canagliflozin and its possible role in the prevention of stroke and albuminuria.

канаглифлозиниНГЛТ-2НГЛТ-1сахарный диабет 2 типаинсультострое нарушение мозгового кровообращенияальбуминуриямикроальбуминуриямакроальбуминурияcanaglifloziniSGLT-2SGLT-1type 2 diabetesstrokealbuminuriamicroalbuminuriamacroalbuminuriaСовет экспертов, результаты которого легли в основу этой статьи, проводился при поддержке ООО «Мерк».ReferencesGregg EW, Menke A. Diabetes and Disability. In: Diabetes in America 3rd edition. National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.Gregg EW, Menke A. Diabetes and Disability. In: Diabetes in America 3rd edition. National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.Дедов И.И., Шестакова М.В., Викулова О.К. и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021 // Сахарный диабет. — 2021. — Т. 24. — №3. — С. 204-221. doi: https://doi.org/10.14341/DM12759Dedov II, Shestakova MV, Vikulova OK, et al.Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-221. (In Russ.). doi: https://doi.org/10.14341/DM12759Yau K, Dharia A, Alrowiyti I, et al. Prescribing SGLT2 Inhibitors in patients with CKD: Expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463-1476. doi: https://doi.org/10.1016/j.ekir.2022.04.094Yau K, Dharia A, Alrowiyti I, et al. Prescribing SGLT2 Inhibitors in patients with CKD: Expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463-1476. doi: https://doi.org/10.1016/j.ekir.2022.04.094Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine. 2021;(36):100933. doi: https://doi.org/10.1016/j.eclinm.2021.100933Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine. 2021;(36):100933. doi: https://doi.org/10.1016/j.eclinm.2021.100933Данные Федерального регистра сахарного диабета Московской области [дата обращения: 01.07.2023].Данные Федерального регистра сахарного диабета Московской области [дата обращения: 01.07.2023]. [Data of the Federal Register of Diabetes Mellitus of the Moscow Region [date of access: 07/01/2023] (In Russ.)]Khan MM, Roberson S, Reid K, et al. Prevalence and predictors of stroke among individuals with prediabetes and diabetes in Florida. BMC Public Health. 2022;22(1):243. doi: https://doi.org/10.1186/s12889-022-12666-3Khan MM, Roberson S, Reid K, et al. Prevalence and predictors of stroke among individuals with prediabetes and diabetes in Florida. BMC Public Health. 2022;22(1):243. doi: https://doi.org/10.1186/s12889-022-12666-3Mosenzon O, Cheng AY, Rabinstein AA, et al. Diabetes and stroke: What are the connections? J Stroke. 2023;25(1):26-38. doi: https://doi.org/10.5853/jos.2022.02306Mosenzon O, Cheng AY, Rabinstein AA, et al. Diabetes and stroke: What are the connections? J Stroke. 2023;25(1):26-38. doi: https://doi.org/10.5853/jos.2022.02306Mac Grory B, Piccini JP, Yaghi S, et al. Hyperglycemia, risk of subsequent stroke, and efficacy of dual antiplatelet therapy: A post hoc analysis of the POINT trial. J Am Heart Assoc. 2022;11(3):e023223. doi: https://doi.org/10.1161/JAHA.121.023223Mac Grory B, Piccini JP, Yaghi S, et al. Hyperglycemia, risk of subsequent stroke, and efficacy of dual antiplatelet therapy: A post hoc analysis of the POINT trial. J Am Heart Assoc. 2022;11(3):e023223. doi: https://doi.org/10.1161/JAHA.121.023223Всероссийское общество неврологов. [Электронный ресурс]. Клинические рекомендации «Ишемический инсульт и транзиторная ишемическая атака у взрослых» 2021. Доступно по: https://cr.minzdrav.gov.ru/recomend/171_2. Ссылка активна на 24.07.2023.All-Russian Society of Neurologists [Internet]. Clinical guidelines «Ischemic stroke and transient ischemic attack in adults» 2021. (In Russ.) Доступно по: https://cr.minzdrav.gov.ru/recomend/171_2. Ссылка активна на 24.07.2023.Daniel K, Wolfe CDA, Busch MA, et al. What Are the Social Consequences of Stroke for Working-Aged Adults? Stroke. 2009;40(6):e431-440. doi: https://doi.org/10.1161/STROKEAHA.108.534487Daniel K, Wolfe CDA, Busch MA, et al. What Are the Social Consequences of Stroke for Working-Aged Adults? Stroke. 2009;40(6):e431-440. doi: https://doi.org/10.1161/STROKEAHA.108.534487Megherbi S-E, Milan C, Minier D, et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke. 2003;34(3):688-694. doi: https://doi.org/10.1161/01.STR.0000057975.15221.40Megherbi S-E, Milan C, Minier D, et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke. 2003;34(3):688-694. doi: https://doi.org/10.1161/01.STR.0000057975.15221.40Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. doi: https://doi.org/10.1056/NEJMoa1611925Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. doi: https://doi.org/10.1056/NEJMoa1611925Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi: https://doi.org/10.1056/NEJMoa1811744Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi: https://doi.org/10.1056/NEJMoa1811744Li J-W, Arnott C, Heerspink HJL, et al. Effect of canagliflozin on total cardiovascular burden in patients with diabetes and chronic Kidney disease: A post hoc analysis from the CREDENCE trial. J Am Heart Assoc. 2022;11(16):e025045. doi: https://doi.org/10.1161/JAHA.121.025045Li J-W, Arnott C, Heerspink HJL, et al. Effect of canagliflozin on total cardiovascular burden in patients with diabetes and chronic Kidney disease: A post hoc analysis from the CREDENCE trial. J Am Heart Assoc. 2022;11(16):e025045. doi: https://doi.org/10.1161/JAHA.121.025045Ang F, Rapattoni W, Bajaj HS, et al. Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial. Eur Heart J. 2022;43(S2):2295-2306. doi: https://doi.org/10.1093/eurheartj/ehac544.2324Ang F, Rapattoni W, Bajaj HS, et al. Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial. Eur Heart J. 2022;43(S2):2295-2306. doi: https://doi.org/10.1093/eurheartj/ehac544.2324Odutayo A, da Costa BR, Pereira TV., et al. Sodium-glucose cotransporter 2 inhibitors, all-cause mortality, and cardiovascular outcomes in adults with type 2 diabetes: A bayesian meta-analysis and meta-regression. J Am Heart Assoc. 2021;10(18):2295-2306. doi: https://doi.org/10.1161/JAHA.120.019918Odutayo A, da Costa BR, Pereira TV., et al. Sodium-glucose cotransporter 2 inhibitors, all-cause mortality, and cardiovascular outcomes in adults with type 2 diabetes: A bayesian meta-analysis and meta-regression. J Am Heart Assoc. 2021;10(18):2295-2306. doi: https://doi.org/10.1161/JAHA.120.019918Tsai W-H, Chuang S-M, Liu S-C, et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep. 2021;11(1):15364. doi: https://doi.org/10.1038/s41598-021-94945-4Tsai W-H, Chuang S-M, Liu S-C, et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep. 2021;11(1):15364. doi: https://doi.org/10.1038/s41598-021-94945-4Qiu M, Ding L-L, Zhou H-R. Comparative efficacy of five SGLT2i on cardiorenal events: A network meta-analysis based on ten CVOTs. Am J Cardiovasc Drugs. 2022;22(1):69-81. doi: https://doi.org/10.1007/s40256-021-00484-8Qiu M, Ding L-L, Zhou H-R. Comparative efficacy of five SGLT2i on cardiorenal events: A network meta-analysis based on ten CVOTs. Am J Cardiovasc Drugs. 2022;22(1):69-81. doi: https://doi.org/10.1007/s40256-021-00484-8Zeng Q, Zhou Q, Liu W, et al. Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure. Front Cardiovasc Med. 2021;8(18):2295-2306. doi: https://doi.org/10.3389/fcvm.2021.636152Zeng Q, Zhou Q, Liu W, et al. Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure. Front Cardiovasc Med. 2021;8(18):2295-2306. doi: https://doi.org/10.3389/fcvm.2021.636152Koepsell H. Glucose transporters in brain in health and disease. Pflugers Arch. 2020;472(9):1299-1343. doi: https://doi.org/10.1007/s00424-020-02441-xKoepsell H. Glucose transporters in brain in health and disease. Pflugers Arch. 2020;472(9):1299-1343. doi: https://doi.org/10.1007/s00424-020-02441-xPawlos A, Broncel M, Wozniak E, et al. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021;26(23):7213. doi: https://doi.org/10.3390/molecules26237213Pawlos A, Broncel M, Wozniak E, et al. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021;26(23):7213. doi: https://doi.org/10.3390/molecules26237213Sayour AA, Olah A, Ruppert M, et al. Pharmacological selectivity of SGLT2 inhibitors and cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis. Eur Heart J. 2022;43(S2):2295-2306. doi: https://doi.org/10.1093/eurheartj/ehac544.2688Sayour AA, Olah A, Ruppert M, et al. Pharmacological selectivity of SGLT2 inhibitors and cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis. Eur Heart J. 2022;43(S2):2295-2306. doi: https://doi.org/10.1093/eurheartj/ehac544.2688Meng Q, Shen Y, Liu D, et al. Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials. J Diabetes Investig. 2016;7(3):359-365. doi: https://doi.org/10.1111/jdi.12417Meng Q, Shen Y, Liu D, et al. Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials. J Diabetes Investig. 2016;7(3):359-365. doi: https://doi.org/10.1111/jdi.12417Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941-950. doi: https://doi.org/10.1016/S0140-6736(13)60683-2Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941-950. doi: https://doi.org/10.1016/S0140-6736(13)60683-2Pfeifer M, Townsend RR, Davies MJ, et al. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16(1):29. doi: https://doi.org/10.1186/s12933-017-0511-0Pfeifer M, Townsend RR, Davies MJ, et al. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16(1):29. doi: https://doi.org/10.1186/s12933-017-0511-0Geng Q, Hou F, Zhang Y, et al. Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis. J Hypertens. 2022;40(5):996-1001. doi: https://doi.org/10.1097/HJH.0000000000003106Geng Q, Hou F, Zhang Y, et al. Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis. J Hypertens. 2022;40(5):996-1001. doi: https://doi.org/10.1097/HJH.0000000000003106Zuo Q, Zhang G, He L, et al. Canagliflozin attenuates hepatic steatosis and atherosclerosis progression in Western Diet-Fed ApoE-Knockout Mice. Drug Des Devel Ther. 2022;(16):4161-4177. doi: https://doi.org/10.2147/DDDT.S388823Zuo Q, Zhang G, He L, et al. Canagliflozin attenuates hepatic steatosis and atherosclerosis progression in Western Diet-Fed ApoE-Knockout Mice. Drug Des Devel Ther. 2022;(16):4161-4177. doi: https://doi.org/10.2147/DDDT.S388823Nasiri-Ansari N, Dimitriadis GK, Agrogiannis G, et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. 2018;17(1):106. doi: https://doi.org/10.1186/s12933-018-0749-1Nasiri-Ansari N, Dimitriadis GK, Agrogiannis G, et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. 2018;17(1):106. doi: https://doi.org/10.1186/s12933-018-0749-1Yaribeygi H, Maleki M, Reiner 2, et al. Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu. J Clin Med. 2022;11(21):6544. doi: https://doi.org/10.3390/jcm11216544Yaribeygi H, Maleki M, Reiner 2, et al. Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu. J Clin Med. 2022;11(21):6544. doi: https://doi.org/10.3390/jcm11216544Ramirez AJ, Sanchez MJ, Sanchez RA. Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril. J Hypertens. 2019;37(3):636-642. doi: https://doi.org/10.1097/HJH.0000000000001907Ramirez AJ, Sanchez MJ, Sanchez RA. Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril. J Hypertens. 2019;37(3):636-642. doi: https://doi.org/10.1097/HJH.0000000000001907Uthman L, Kuschma M, Romer G, et al. Novel anti-inflammatory effects of canagliflozin involving Hexokinase II in lipopolysaccharide-stimulated human coronary artery endothelial cells. Cardiovasc Drugs Ther. 2021;35(6):1083-1094. doi: https://doi.org/10.1007/s10557-020-07083-wUthman L, Kuschma M, Romer G, et al. Novel anti-inflammatory effects of canagliflozin involving Hexokinase II in lipopolysaccharide-stimulated human coronary artery endothelial cells. Cardiovasc Drugs Ther. 2021;35(6):1083-1094. doi: https://doi.org/10.1007/s10557-020-07083-wLi C, Yu J, Hockham C, et al. Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. Diabetes Obes Metab. 2022;24(10):1927-1938. doi: https://doi.org/10.1111/dom.14772Li C, Yu J, Hockham C, et al. Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. Diabetes Obes Metab. 2022;24(10):1927-1938. doi: https://doi.org/10.1111/dom.14772Pinto LC, Rados DV, Remonti LR, et al. Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. Arch Endocrinol Metab. 2022;66(1):68-76. doi: https://doi.org/10.20945/2359-3997000000440Pinto LC, Rados DV, Remonti LR, et al. Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. Arch Endocrinol Metab. 2022;66(1):68-76. doi: https://doi.org/10.20945/2359-3997000000440Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodiumglucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783-794. doi: https://doi.org/10.1111/dom.12670Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodiumglucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783-794. doi: https://doi.org/10.1111/dom.12670Инструкция по применению лекарственного препарата Инвокана® ЛП-002977. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7e19c450-bd8a-4fa4-a9f1-f789b8515544&t=). Ссылка активна на 23.10.2023.The Instructions for Use of INVOKANA® LP-002977. (In Russ.). Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7e19c450-bd8a-4fa4-a9f1-f789b8515544&t=). Ссылка активна на 23.10.2023.Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7-11. doi: https://doi.org/10.1016/j.kisu.2021.11.003Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7-11. doi: https://doi.org/10.1016/j.kisu.2021.11.003Sundstrom J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2-4 million patients from 11 countries: The CaReMe CKD study. Lancet Reg Heal-Eur. 2022;20(1):100438. doi: https://doi.org/10.1016/j.lanepe.2022.100438Sundstrom J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2-4 million patients from 11 countries: The CaReMe CKD study. Lancet Reg Heal-Eur. 2022;20(1):100438. doi: https://doi.org/10.1016/j.lanepe.2022.100438Алгоритмы специализированной медицинской помощи больным сахарным диабетом 11-й выпуск./ Под ред. Дедова И.И., Шестаковой М.В., Майорова А.Ю.. — М.; 2023. doi: https://doi.org/10.14341/DM13042Standards of specialized diabetes care. 11th edition. Ed by Dedov II, Shestakova MV, Mayorov AYu. Moscow, 2023 (In Russ.) doi: https://doi.org/10.14341/DM13042Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514-525. doi: https://doi.org/10.1016/S2213-8587(15)00040-6Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514-525. doi: https://doi.org/10.1016/S2213-8587(15)00040-6Tonneijck L, Muskiet MHA, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023-1039. doi: https://doi.org/10.1681/ASN.2016060666Tonneijck L, Muskiet MHA, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023-1039. doi: https://doi.org/10.1681/ASN.2016060666Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. doi: https://doi.org/10.2215/CJN.11491116Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. doi: https://doi.org/10.2215/CJN.11491116D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003;63(3):809-825. doi: https://doi.org/10.1046/j.1523-1755.2003.00840.xD'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003;63(3):809-825. doi: https://doi.org/10.1046/j.1523-1755.2003.00840.xBalazki P, Schaller S, Eissing T, et al. A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors. CPT Pharmacometrics Syst Pharmacol. 2018;7(12):788-797. doi: https://doi.org/10.1002/psp4.12359Balazki P, Schaller S, Eissing T, et al. A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors. CPT Pharmacometrics Syst Pharmacol. 2018;7(12):788-797. doi: https://doi.org/10.1002/psp4.12359Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99. doi: https://doi.org/10.1186/s12933-019-0903-4Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99. doi: https://doi.org/10.1186/s12933-019-0903-4Gohda T, Murakoshi M. Sodium-glucose cotransporter-2 inhibitors— miracle drugs for the treatment of chronic Kidney disease irrespective of the diabetes status: Lessons from the dedicated kidney disease-focused CREDENCE and DAPA-CKD trials. Int J Mol Sci. 2022;23(22):13749. doi: https://doi.org/10.3390/ijms232213749Gohda T, Murakoshi M. Sodium-glucose cotransporter-2 inhibitors— miracle drugs for the treatment of chronic Kidney disease irrespective of the diabetes status: Lessons from the dedicated kidney disease-focused CREDENCE and DAPA-CKD trials. Int J Mol Sci. 2022;23(22):13749. doi: https://doi.org/10.3390/ijms232213749Durkin M, Blais J. Linear projection of estimated glomerular filtration rate decline with canagliflozin and implications for dialysis utilization and cost in diabetic nephropathy. Diabetes Ther. 2021;12(2):499-508. doi: https://doi.org/10.1007/s13300-020-00953-4Durkin M, Blais J. Linear projection of estimated glomerular filtration rate decline with canagliflozin and implications for dialysis utilization and cost in diabetic nephropathy. Diabetes Ther. 2021;12(2):499-508. doi: https://doi.org/10.1007/s13300-020-00953-4Tziomalos K, Athyros VG. Diabetic nephropathy: New risk factors and improvements in diagnosis. Rev Diabet Stud. 2015;12(1-2):110-118. doi: https://doi.org/10.1900/RDS.2015.12.110Tziomalos K, Athyros VG. Diabetic nephropathy: New risk factors and improvements in diagnosis. Rev Diabet Stud. 2015;12(1-2):110-118. doi: https://doi.org/10.1900/RDS.2015.12.110Zhang J, Wei J, Jiang S, et al. Macula densa SGLT1-NOS1-tubuloglomerular feedback pathway, a new mechanism for glomerular hyperfiltration during hyperglycemia. J Am Soc Nephrol. 2019;30(4):578-593. doi: https://doi.org/10.1681/ASN.2018080844Zhang J, Wei J, Jiang S, et al. Macula densa SGLT1-NOS1-tubuloglomerular feedback pathway, a new mechanism for glomerular hyperfiltration during hyperglycemia. J Am Soc Nephrol. 2019;30(4):578-593. doi: https://doi.org/10.1681/ASN.2018080844Hsieh C-Y, Sung S-F. From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors. Int J Mol Sci. 2022;24(1):351. doi: https://doi.org/10.3390/ijms24010351Hsieh C-Y, Sung S-F. From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors. Int J Mol Sci. 2022;24(1):351. doi: https://doi.org/10.3390/ijms24010351

The authors declare that there are no conflicts of interest present.